Literature DB >> 1335414

kappa-Opioid binding sites on a murine lymphoma cell line.

J M Bidlack1, L D Saripalli, D M Lawrence.   

Abstract

As a first step in determining whether any subset of lymphocytes expresses opioid receptors, membranes prepared from mouse lymphoma cell lines were screened for [3H]naloxone binding sites. Membranes from the R1.1 cell line specifically bound [3H]naloxone. The Hill coefficient for [3H]naloxone binding was 0.93 +/- 0.18, and nonlinear regression analysis indicated that a one-site model was the best fit of the [3H[naloxone saturation binding data. Low concentrations of kappa-selective opioids, but neither mu nor delta opioids, inhibited [3H]naloxone binding. Saturation binding studies with the kappa-selective compound [3H]U69,593 revealed a single binding site with a KD value of 0.204 +/- 0.039 nM and a Bmax value of 31.7 +/- 3.1 fmol/mg of membrane protein. The Hill coefficient for [3H]U69,593 binding was 1.03 +/- 0.11, indicative of a single site. Time courses for the association and dissociation of [3H]U69,593 binding at 25 degrees C exhibited properties consistent with a single class of binding sites. Low concentrations of kappa-selective opioids, including dynorphin peptides, inhibited [3H]U69,593 binding, while high concentrations of mu opioids were needed to inhibit binding, and the delta-selective ligands were ineffective at concentrations up to 10 microM. Stereoselectivity of the binding site was demonstrated by the finding that the Ki value for (-)-pentazocine in inhibiting [3H]U69,593 binding was 25 times less than for the (+)-isomer. Based on its high affinity for U69,593, alpha-neo-endorphin, and dynorphin B, the kappa opioid binding site on R1.1 cell membranes belongs to the kappa 1b subtype. As observed with brain kappa opioid binding sites, sodium inhibited [3H]U69,593 binding to R1.1 cell membranes in a concentration-dependent manner. These data demonstrate that the murine lymphoma cell line R1.1 expresses kappa opioid binding sites that are very similar to brain kappa opioid binding sites.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335414     DOI: 10.1016/0922-4106(92)90003-e

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  Detection and function of opioid receptors on cells from the immune system.

Authors:  J M Bidlack
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

Review 2.  Opioid receptors and signaling on cells from the immune system.

Authors:  Jean M Bidlack; Maxim Khimich; Amy L Parkhill; Sarah Sumagin; Baoyong Sun; Christopher M Tipton
Journal:  J Neuroimmune Pharmacol       Date:  2006-07-08       Impact factor: 4.147

3.  kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression.

Authors:  C C Chao; G Gekker; S Hu; W S Sheng; K B Shark; D F Bu; S Archer; J M Bidlack; P K Peterson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

Review 4.  Injecting drugs of abuse and immunity: implications for HIV vaccine testing and efficacy.

Authors:  Kenneth E Ugen; Susan B Nyland
Journal:  Springer Semin Immunopathol       Date:  2006-10-13

Review 5.  Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression.

Authors:  M J Finley; C M Happel; D E Kaminsky; T J Rogers
Journal:  Cell Immunol       Date:  2008-02-14       Impact factor: 4.868

6.  Bi-directional heterologous desensitization between the major HIV-1 co-receptor CXCR4 and the kappa-opioid receptor.

Authors:  Matthew J Finley; Xiaohong Chen; Guiseppe Bardi; Penny Davey; Ellen B Geller; Lily Zhang; Martin W Adler; Thomas J Rogers
Journal:  J Neuroimmunol       Date:  2008-06-03       Impact factor: 3.478

7.  Identification of kappa opioid receptors in the immune system by indirect immunofluorescence.

Authors:  D M Lawrence; W el-Hamouly; S Archer; J F Leary; J M Bidlack
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

8.  Kappa Opioid Receptor Expression and Function in Cells of the Immune System.

Authors:  Thomas J Rogers
Journal:  Handb Exp Pharmacol       Date:  2022
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.